• Explore /
  • Poster
  • / mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.

Abstract Poster

Authors

null

Tim Meyer

UCL Cancer Institute, University College London, London, United Kingdom

Tim Meyer , Daniel H. Palmer , Ann-Lii Cheng , Julia Hocke , Arsene-Bienvenu Loembe , Chia-Jui Yen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01004003 and NCT00987935

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4086)

DOI

10.1200/JCO.2016.34.15_suppl.4086

Abstract #

4086

Poster Bd #

78

Abstract Disclosures

Similar Posters

First Author: Ahmed Omar Kaseb

First Author: Imane H. El Dika

First Author: Mingyue Cai

First Author: Jaekyung Cheon